- cafead   Sep 27, 2021 at 10:52: AM
via Biohaven Pharma's latest update on its Phase III clinical trial to use verdiperstat as a potential treatment for multiple system atrophy (MSA) showed that it did not meet its expected outcomes.
article source
article source